Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH/ISH 2016 | What’s next for MPN?

Ruben Mesa • 18 Apr 2016
BSH/ISH 2016
Myeloproliferative Neoplasms Imetelstat Pacritinib

Ruben Mesa, MD, from the Mayo Clinic, Scottsdale, AZ, USA discusses current developments in myeloproliferative neoplasms (MPNs) at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH) held in Glasgow, Scotland. According to Dr Mesa, it is a very exciting time for MPNs as new JAK inhibitors such as pacritinib and NS-018, anti-fibrosing agents such as PRM-151 as well as telomerase inhibitors such as imetelstat, are being developed.

More from Ruben Mesa

2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
2:08
Real-world analysis of the MOST study: factors impacting progression to MF in patients with ET
Ruben Mesa • 9 Dec 2023
2:26
Assessing the impact of momelotinib on transfusion burden in MF: analysis of SIMPLIFY-1 & MOMENTUM
Ruben Mesa • 9 Dec 2023
2:20
Quantifying the anemia benefit of momelotinib in MF: analysis of data from SIMPLIFY-1 & SIMPLIFY-2
Ruben Mesa • 9 Dec 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals